Investing.com -- Cardiff Oncology Inc (NASDAQ:CRDF)公布的第二季度业绩未能达到分析师预期,导致股价暴跌22%,尽管收入超过预估,但投资者对亏损超出预期做出了负面反应。 这家临床阶段生物技术公司在2025年第二季度录得每股亏损0.21美元,未能达到分析师预期的每股亏损0.19美元。收入为12万美元,超过了9.643万美元的一致预期。公司运营支出增至...
Source LinkInvesting.com -- Cardiff Oncology Inc (NASDAQ:CRDF)公布的第二季度业绩未能达到分析师预期,导致股价暴跌22%,尽管收入超过预估,但投资者对亏损超出预期做出了负面反应。 这家临床阶段生物技术公司在2025年第二季度录得每股亏损0.21美元,未能达到分析师预期的每股亏损0.19美元。收入为12万美元,超过了9.643万美元的一致预期。公司运营支出增至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.